Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation
Open accessThe DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-beta (Aβ) aggregation, tau pathology, and chronic neuroinflammation. Among these, neuroinflammation plays a crucial role in exacerbating disease progression, making it an attractive therapeutic target. However, the presence of the blood-brain barrier (BBB) significantly limits the effective delivery of therapeutic agents to the brain, necessitating novel drug delivery strategies. Nanocarrier-based delivery systems have emerged as a promising solution to these challenges, offering targeted drug transport, enhanced BBB penetration, and improved bioavailability while minimizing systemic toxicity. This review explores the current advancements in nanocarrier-mediated drug delivery for AD, focusing on the mechanisms of neuroinflammation, the role of nanocarriers in overcoming the BBB, and their ability to modulate inflammatory pathways. Furthermore, the review discusses preclinical validation strategies and key challenges, including safety concerns, large-scale production limitations, and regulatory hurdles that must be addressed to enable clinical translation. Future perspectives emphasize the integration of nanotechnology with precision medicine, gene therapy, and artificial intelligence to optimize nanocarrier design for individualized AD treatment. By overcoming these obstacles, nanocarriers hold the potential to revolutionize therapeutic approaches for AD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other limitations include off-target effects because of drug interaction with unwanted cells, disease heterogeneity demanding biomarker-driven patient classification for a personalized therapy, regulations, pricing, social considerations, and so on [127,129].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [129]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Altogether, they must guarantee that the repeated and long-term administration of the medicine poses no risk of neural damage, since even the slightest perturbation might produce irreversible damage [129].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [129]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many nanoparticle-based AD therapies have failed in clinical trials, primarily due to poor BBB penetration and low brain delivery, as well as promiscuous peripheral accumulation, which limits efficacy and raises toxicity concerns [182].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,904
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950 · cited 2×
“These fi ndings suggest that Lf-TMC NPs can effectively improve the distribution of the drug in the brain, thereby enhancing therapeutic ef fi cacy in AD treatment (Meng et al., 2018).”
Global estimates on the number of persons across the Alzheimer's disease continuum
Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12694 · Cited by 895
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837 · cited 1×
“Nanocarriers, including liposomes, polymeric nanoparticles, and dendrimers, offer a promising platform for the targeted delivery of drugs to the brain (Zhou et al., 2018; Saeedi et al., 2019).”
Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease
Bai, R., Guo, J., Ye, X.-Y., Xie, Y., & Xie, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101619 · Cited by 813 · cited 1×
“One of the key mechanisms through which neuroin fl ammation accelerates AD is the promotion of oxidative stress (Bai et al., 2022).”
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.937486 · Cited by 703 · cited 1×
“Alzheimer ’ s disease (AD), a progressive neurodegenerative disorder (Scheltens et al., 2021), remains one of the leading causes of dementia worldwide, affecting millions of individuals and placing an immense socioeconomic burden on healthcare systems (Li et al., 2022).”
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Park, M. W., Cha, H. W., Kim, J., Kim, J. H., Yang, H., Yoon, S., Boonpraman, N., Yi, S. S., Yoo, I. D., & Moon, J.-S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101947 · Cited by 683
A rotarod test for evaluation of motor skill learning
Shiotsuki, H., Yoshimi, K., Shimo, Y., Funayama, M., Takamatsu, Y., Ikeda, K., Takahashi, R., Kitazawa, S., & Hattori, N. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.03.026 · Cited by 627
Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy
Chen, X., Firulyova, M., Manis, M., Herz, J., Smirnov, I., Aladyeva, E., Wang, C., Bao, X., Finn, M. B., Hu, H., et al. (2023) · Nature · doi:10.1038/s41586-023-05788-0 · Cited by 609
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604 · cited 1×
“However, this strategy is inherently limited by factors such as the brain ’ s pathological state and the physicochemical properties of the nanocarriers, including their size, surface charge, and the nature of the coating (Xie et al., 2019).”
Morris Water Maze Test for Learning and Memory Deficits in Alzheimer's Disease Model Mice
Bromley-Brits, K., Deng, Y., & Song, W. (2011) · Journal of Visualized Experiments · doi:10.3791/2920 · Cited by 583
Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis
Das, S. S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., & Kyzas, G. Z. (2020) · Polymers · doi:10.3390/polym12061397 · Cited by 581 · cited 1×
“Additionally, stimuli-responsive nanocarriers that release their therapeutic payloads in response to speci fi c triggers (e.g., changes in pH, temperature, or enzymatic activity) can reduce non-speci fi c drug release, ensuring that the drug is only released at the target site (Das et al., 2020).”
Ng, A., Tam, W. W., Zhang, M. W., Ho, C. S., Husain, S. F., McIntyre, R. S., & Ho, R. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-30487-6 · Cited by 572
Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease
Singh, D. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02565-0 · Cited by 569 · cited 1×
“In particular, the cytokines TNF-α , IL-1 β , and IL-6 have been implicated in driving the in fl ammatory response in AD (Singh, 2022).”
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040883 · Cited by 531
Microglia regulate central nervous system myelin growth and integrity
McNamara, N. B., Munro, D. A. D., Bestard-Cuche, N., Uyeda, A., Bogie, J. F. J., Hoffmann, A., Holloway, R. K., Molina-Gonzalez, I., Askew, K. E., Mitchell, S., et al. (2023) · Nature · doi:10.1038/s41586-022-05534-y · Cited by 507 · cited 1×
“Under normal conditions, microglia act as the primary defenders of the central nervous system (CNS), responding to damage and maintaining homeostasis through phagocytosis and the release of pro-in fl ammatory cytokines (McNamara et al., 2023).”
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450
Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease
Gerrits, E., Brouwer, N., Kooistra, S. M., Woodbury, M. E., Vermeiren, Y., Lambourne, M., Mulder, J., Kummer, M., Möller, T., Biber, K., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02263-w · Cited by 441
Roles of neuropathology-associated reactive astrocytes: a systematic review
Lawrence, J. M., Schardien, K., Wigdahl, B., & Nonnemacher, M. R. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01526-9 · Cited by 433
Traumatic Brain Injury and Risk of Neurodegenerative Disorder
Brett, B. L., Gardner, R. C., Godbout, J., Dams-O’Connor, K., & Keene, C. D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.025 · Cited by 430
Chen, H., Kim, S., Li, L., Wang, S., Park, K., & Cheng, J.-X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707046105 · Cited by 394
Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation
Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355 · cited 1×
“Moreover, neuroin fl ammatory biomarkers like C-reactive protein (CRP) or TNF-α can indicate the presence of neuroin fl ammation, suggesting that patients with elevated levels of these biomarkers may bene fi t from nanocarriers targeting neuroin fl ammation (Carter et al., 2019; Lista et al., 2024).”
Alzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.03.024 · Cited by 334
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Meng, Q., Wang, A., Hua, H., Jiang, Y., Wang, Y., Mu, H., Wu, Z., & Sun, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s151474 · Cited by 310
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
Blood-Brain Barrier Overview: Structural and Functional Correlation
Alahmari, A. (2021) · Neural Plasticity · doi:10.1155/2021/6564585 · Cited by 299 · cited 2×
“Extracted from author Abeer Alahmari (Alahmari, 2021).”
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
Lopez‐Rodriguez, A. B., Hennessy, E., Murray, C. L., Nazmi, A., Delaney, H. J., Healy, D., Fagan, S. G., Rooney, M., Stewart, E., Lewis, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12341 · Cited by 293
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease
Otero-Garcia, M., Mahajani, S. U., Wakhloo, D., Tang, W., Xue, Y.-Q., Morabito, S., Pan, J., Oberhauser, J., Madira, A. E., Shakouri, T., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.021 · Cited by 262
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Propson, N. E., Roy, E. R., Litvinchuk, A., Köhl, J., & Zheng, H. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140966 · Cited by 258
Goshi, N., Morgan, R. K., Lein, P. J., & Seker, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01819-z · Cited by 242
Dendrimers in the context of nanomedicine
Dias, A. P., da Silva Santos, S., da Silva, J. V., Parise-Filho, R., Igne Ferreira, E., Seoud, O. E., & Giarolla, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118814 · Cited by 241 · cited 1×
“…nanocarrier systems, liposomes, polymeric nanoparticles, and dendritic polymers have emerged as particularly promising platforms, each exhibiting distinct advantages in terms of drug stability, release kinetics, and biocompatibility (Nakamura et al., 2022; Beach et al., 2024; Dias et al., 2020).”
Novel nano-drug delivery system for natural products and their application
Huang, L., Huang, X.-H., Yang, X., Hu, J.-Q., Zhu, Y.-Z., Yan, P.-Y., & Xie, Y. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107100 · Cited by 237
Maiti, P., & Dunbar, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061637 · Cited by 233 · cited 1×
“Despite its promising biological activities, the clinical application of curcumin is limited by its poor solubility, rapid clearance, and low stability (Maiti and Dunbar, 2018).”
Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery
Zelepukin, I. V., Shevchenko, K. G., & Deyev, S. M. (2024) · Nature Communications · doi:10.1038/s41467-024-48838-5 · Cited by 224 · cited 1×
“Nanocarriers are designed to cross the BBB and deliver therapeutic agents to the CNS, but their accumulation in non-target tissues or the brain could lead to toxicity or diminish their therapeutic ef fi cacy (Blanco et al., 2015; Zelepukin et al., 2024).”
Dendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 213 · cited 1×
“Behavioral assessments play a pivotal role in evaluating the therapeutic effects of nanocarriers on cognitive and motor functions in AD animal models (Puzzo et al., 2014).”
Huo, X., Zhang, Y., Jin, X., Li, Y., & Zhang, L. (2019) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2018.11.008 · Cited by 211 · cited 1×
“In order to solve this problem, Huo et al. (2019) enhanced the solubility, stability, and bioavailability of curcumin by encapsulating it in selenium nanoparticles (Se-NP)-coated poly (lactic-co-glycolic acid) (PLGA) nanospheres.”
Choudhury, H., Pandey, M., Chin, P. X., Phang, Y. L., Cheah, J. Y., Ooi, S. C., Mak, K.-K., Pichika, M. R., Kesharwani, P., Hussain, Z., et al. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0552-2 · Cited by 209
Ni, X.-C., Wang, H.-F., Cai, Y.-Y., Yang, D., Alolga, R. N., Liu, B., Li, J., & Huang, F.-Q. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102363 · Cited by 208 · cited 1×
“Microglia and astrocytes generate ROS as part of their immune response, which, in excess, can damage neurons, synapses, and blood vessels (Kim et al., 2022; Ni et al., 2022).”
Self-citationGlial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
Stealth and pseudo-stealth nanocarriers
Wen, P., Ke, W., Dirisala, A., Toh, K., Tanaka, M., & Li, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114895 · Cited by 201
Self-citationMicroglial Piezo1 senses Aβ fibril stiffness to restrict Alzheimer’s disease
Hu, J., Chen, Q., Zhu, H., Hou, L., Liu, W., Yang, Q., Shen, H., Chai, G., Zhang, B., Chen, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.021 · Cited by 193
How neurons die in Alzheimer's disease: Implications for neuroinflammation
Mangalmurti, A., & Lukens, J. R. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102575 · Cited by 186
Pagels, R. F., & Prud'homme, R. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.001 · Cited by 183
Loureiro, J. A., Gomes, B., Fricker, G., Coelho, M. A. N., Rocha, S., & Pereira, M. C. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.04.041 · Cited by 179
Epigenetics of Alzheimer’s Disease
Nikolac Perkovic, M., Videtic Paska, A., Konjevod, M., Kouter, K., Svob Strac, D., Nedic Erjavec, G., & Pivac, N. (2021) · Biomolecules · doi:10.3390/biom11020195 · Cited by 176
Drug Delivery with polymeric nanocarriers-cellular uptake mechanisms
Nelemans, L. C., & Gurevich, L. (2020) · Materials · doi:10.3390/ma13020366 · Cited by 173
Juhairiyah, F., & de Lange, E. C. M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00648-z · Cited by 172
Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain
Ogawa, K., Kato, N., Yoshida, M., Hiu, T., Matsuo, T., Mizukami, S., Omata, D., Suzuki, R., Maruyama, K., Mukai, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.042 · Cited by 161
Kosel, F., Pelley, J. M. S., & Franklin, T. B. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.012 · Cited by 160
Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes
Mazumdar, H., Khondakar, K. R., Das, S., Halder, A., & Kaushik, A. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2440618 · Cited by 159
Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.034 · Cited by 158
CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Bhardwaj, S., Kesari, K. K., Rachamalla, M., Mani, S., Ashraf, G. M., Jha, S. K., Kumar, P., Ambasta, R. K., Dureja, H., Devkota, H. P., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.001 · Cited by 158
Zhong, G., Long, H., Zhou, T., Liu, Y., Zhao, J., Han, J., Yang, X., Yu, Y., Chen, F., & Shi, S. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121690 · Cited by 151
Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?
Satalkar, P. P., Elger, B. S., & Shaw, D. (2015) · Science and Engineering Ethics · doi:10.1007/s11948-015-9705-6 · Cited by 143
Kang, T., Jiang, M., Jiang, D., Feng, X., Yao, J., Song, Q., Chen, H., Gao, X., & Chen, J. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00222 · Cited by 139
Kim, S., Lee, W., Jo, H., Sonn, S.-K., Jeong, S.-J., Seo, S., Suh, J., Jin, J., Kweon, H. Y., Kim, T. K., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102347 · Cited by 139
Gao, X. J., Ciura, K., Ma, Y., Mikołajczyk, A., Jagiełło, K., Wan, Y., Gao, Y., Zheng, J., Zhong, S., Puzyn, T., et al. (2024) · Advanced Materials · doi:10.1002/adma.202407793 · Cited by 139
Yang, X., Yang, W., Xia, X., Lei, T., Yang, Z., Jia, W., Zhou, Y., Cheng, G., & Gao, H. (2022) · Small · doi:10.1002/smll.202203182 · Cited by 133
Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors
Kesharwani, P., & Gupta, U. (2018) · Elsevier eBooks · doi:10.1016/c2016-0-03390-9 · Cited by 131
Kummer, M. P., Ising, C., Kummer, C., Sarlus, H., Griep, A., Vieira‐Saecker, A., Schwartz, S., Halle, A., Brückner, M., Händler, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108662 · Cited by 127
The efficacy and safety of memantine for the treatment of Alzheimer’s disease
Matsunaga, S., Kishi, T., Nomura, I., Sakuma, K., Okuya, M., Ikuta, T., & Iwata, N. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1524870 · Cited by 125
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
Griffin, B. T., Guo, J., Presas, E., Donovan, M. D., Alonso, M. J., & O’Driscoll, C. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.006 · Cited by 120
Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease
Yang, Y., Tapias, V., Acosta, D., Xu, H., Chen, H., Bhawal, R., Anderson, E. T., Ivanova, E., Lin, H., Sagdullaev, B. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27572-2 · Cited by 118
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 116
Microglia-Astrocyte Communication in Alzheimer’s Disease
Wu, Y., & Eisel, U. L. M. (2023) · Journal of Alzheimer’s Disease · doi:10.3233/jad-230199 · Cited by 111 · cited 2×
“However, in AD, this protective response becomes dysregulated, and chronic activation of microglia and astrocytes is observed, exacerbating neuronal damage and promoting the progression of neurodegeneration (Jor fi et al., 2023; Wu and Eisel, 2023).”
‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 106 · cited 1×
“Lipid-based nanoparticles, including liposomes and solid lipid NPs (SLNs), are particularly effective due to their stability and ability to encapsulate both hydrophilic and hydrophobic drugs, making them suitable for targeting the brain (Fu et al., 2023).”
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
Zhu, F.-D., Hu, Y.-J., Yu, L., Zhou, X.-G., Wu, J.-M., Tang, Y., Qin, D.-L., Fan, Q.-Z., & Wu, A.-G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683935 · Cited by 104
Oral Nanomedicine: Challenges and Opportunities
Deng, B., Liu, S., Wang, Y., Ali, B., Kong, N., Xie, T., Koo, S., Ouyang, J., & Tao, W. (2023) · Advanced Materials · doi:10.1002/adma.202306081 · Cited by 101
Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration
Wang, J., Ni, Q., Wang, Y., Zhang, Y., He, H., Gao, D., Ma, X., & Liang, X.-J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.045 · Cited by 99
Fan, W., Peng, H., Yu, Z., Wang, L., He, H., Ma, Y., Qi, J., Lü, Y., & Wu, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.016 · Cited by 98
Taylor, X., Clark, I. M., Fitzgerald, G. J., Oluoch, H., Hole, J. T., DeMattos, R. B., Wang, Y., & Pan, F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00649-w · Cited by 94
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Khemka, S., Reddy, A., Garcia, R. I., Jacobs, M., Reddy, R. P., Roghani, A. K., Pattoor, V., Basu, T., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102091 · Cited by 88 · cited 1×
“Environmental factors, including head trauma, cardiovascular diseases, and diabetes, have also been implicated in elevating the risk of developing AD (Brett et al., 2022; Khemka et al., 2023).”
Nuclear imaging approaches facilitating nanomedicine translation
Pérez‐Medina, C., Teunissen, A. J. P., Kluza, E., Mulder, W. J. M., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.017 · Cited by 86
Immune Activation in Alzheimer Disease
Mary, A., Mancuso, R., & Heneka, M. T. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035222 · Cited by 85 · cited 1×
“This activation is marked by changes in their morphology and the release of in fl ammatory mediators such as pro-in fl ammatory cytokines, chemokines, and ROS (Johnson et al., 2020; Mary et al., 2024).”
In vitro toxicity assessment of oral nanocarriers
Ciappellano, S. G., Tedesco, E., Venturini, M., & Benetti, F. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.007 · Cited by 84
Model‐Informed Artificial Intelligence: Reinforcement Learning for Precision Dosing
Ribba, B., Dudal, S., Lavé, T., & Peck, R. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1777 · Cited by 82
Silva-Abreu, M., Calpena, A. C., Andrés-Benito, P., Aso, E., Romero, I. A., Roig-Carles, D., Gromnicova, R., Espina, M., Ferrer, I., García, M. L., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s171490 · Cited by 81
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
Huang, Q., Jiang, C., Xia, X., Wang, Y., Yan, C., Wang, X., Lei, T., Yang, X., Yang, W., Cheng, G., et al. (2023) · Research · doi:10.34133/research.0180 · Cited by 78
Polymer Directed Self-Assembly of pH-Responsive Antioxidant Nanoparticles
Tang, C., Amin, D. R., Messersmith, P. B., Anthony, J. E., & Prud’homme, R. K. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b00213 · Cited by 77
Ligand-based active targeting strategies for cancer theranostics
Bandyopadhyay, A., Das, T., Nandy, S., Sahib, S., Preetam, S., Gopalakrishnan, A. V., & Dey, A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02612-4 · Cited by 77
Alzheimer’s Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs
McGeer, P. L., Guo, J. P., Lee, M., Kennedy, K., & McGeer, E. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170706 · Cited by 76
Intravital microscopy reveals a novel mechanism of nanoparticles excretion in kidney
Naumenko, V., Nikitin, A., Kapitanova, K., Melnikov, P., Vodopyanov, S., Garanina, A., Valikhov, M., Ilyasov, A., Vishnevskiy, D., Markov, A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.026 · Cited by 76
Jing, B., Gai, Y., Qian, R., Liu, Z., Zhu, Z., Gao, Y., Lan, X., & An, R. F. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00746-8 · Cited by 73
Qiao, L., Chen, Y., Song, X., Dou, X., & Xu, C. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s374024 · Cited by 73
Gopalan, D., Pandey, A., Udupa, N., & Mutalik, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.034 · Cited by 72
Guo, Y., Chen, W., Wang, W., Shen, J., Guo, R., Gong, F., Lin, S., Cheng, D., Chen, G., & Shuai, X. (2012) · ACS Nano · doi:10.1021/nn3037573 · Cited by 70
Abbas, H., Refai, H., El Sayed, N., Rashed, L. A., Mousa, M. R., & Zewail, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121244 · Cited by 68
Transferrin receptor 1 targeted nanomedicine for brain tumor therapy
Li, J., Zhang, Z., Zhang, B., Yan, X., & Fan, K. (2023) · Biomaterials Science · doi:10.1039/d2bm02152h · Cited by 66
Self-citationXie, A., Cheng, G., Wu, J., Li, Z., Yu, G., Zhu, X., & Chen, T. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122749 · Cited by 65
Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer’s disease therapy
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122167 · Cited by 63
Encapsulation of Curcumin in Polystyrene-Based Nanoparticles—Drug Loading Capacity and Cytotoxicity
Zatorska, M., Łazarski, G., Maziarz, U., Foryś, A., Trzebicka, B., Wnuk, D., Chołuj, K., Karewicz, A., Michalik, M., Jamróz, D., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c00867 · Cited by 59
Cytotoxicity and genotoxicity of lipid nanocapsules
Roux, G. L., Moche, H., Nieto, A., Benoît, J., Nesslany, F., & Lagarce, F. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.03.007 · Cited by 58
Polymeric Nanoparticles for Brain Drug Delivery - A Review
Raman, S., Mahmood, S., Hilles, A. R., Javed, M. N., Azmana, M., & AL-Japairai, K. A. S. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200508074348 · Cited by 57
Xie, J., Tian, S., Zhang, H., Feng, C., Han, Y., Dai, H., & Yan, L. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00134 · Cited by 57
Liu, Y., Jiang, Z., Hou, X., Xie, X., Shi, J., Shen, J., He, Y., Wang, Z., & Feng, N. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102075 · Cited by 56
Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity
Bhattacharjee, S. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00033 · Cited by 54 · cited 1×
“Beyond providing protection against enzymatic degradation, encapsulation signi fi cantly enhances both drug stability and bioavailability (Bhattacharjee, 2022).”
Physicochemical properties, pharmacokinetics, toxicology and application of nanocarriers
Cai, X., Jin, M. F., Yao, L., He, B., Ahmed, S., Safdar, W., Ahmad, I., Cheng, D., Lei, Z., & Sun, T. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb02001g · Cited by 53 · cited 1×
“Additionally, nanocarriers can enhance the pharmacokinetics and bioavailability of drugs, while minimizing systemic toxicity (Wen et al., 2023; Cai et al., 2023).”
Engineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction
Pavlou, G., Spitz, S., Pramotton, F. M., Tsai, A., Li, B. M., Wang, X., Barr, O. M., Ko, E. C., Zhang, S., Ashley, S. J., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122864 · Cited by 53 · cited 1×
“Speci fi cally, there is a need for standardized 3D models of the BBB to evaluate nanocarrier penetration and targeting (Pavlou et al., 2025).”
Musumeci, T., Benedetto, G. D., Carbone, C., Bonaccorso, A., Amato, G., Faro, M. J. L., Burgaletto, C., Puglisi, G., Bernardini, R., & Cantarella, G. (2022) · Biomedicines · doi:10.3390/biomedicines10050985 · Cited by 52
Recent progress of nanomedicine in the treatment of Alzheimer’s disease
Hu, L., Tao, Y., Jiang, Y., & Qin, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1228679 · Cited by 52
Liang, R., Li, F., Chen, X., Tan, F., Lan, T., Yang, J., Liao, J., Yang, Y., & Liu, N. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11098 · Cited by 52
Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration
Malpetti, M., Swann, P., Tsvetanov, K. A., Chouliaras, L., Strauss, A., Chikaura, T., Murley, A. G., Ashton, N. J., Barker, P. J., Jones, P. S., et al. (2024) · Brain · doi:10.1093/brain/awae269 · Cited by 52
Liposomal Conjugates for Drug Delivery to the Central Nervous System
Helm, F., & Fricker, G. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7020027 · Cited by 51
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 50
Yuan, X., Jia, Z., Li, J., Liu, Y., Huang, Y., Gong, Y., Guo, X., Chen, X., Cen, J., & Liu, J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01290h · Cited by 46
Self-citationNanobottles for Controlled Release and Drug Delivery
Qiu, J., Xu, J., & Younan Xia, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000587 · Cited by 44
Electrically pulsatile responsive drug delivery platform for treatment of Alzheimer’s disease
Wu, L., Wang, J., Gao, N., Ren, J., Zhao, A., & Qu, X. (2015) · Nano Research · doi:10.1007/s12274-015-0750-x · Cited by 43
Sarathlal, K. C., Kakoty, V., Marathe, S. A., Chitkara, D., & Taliyan, R. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00258-1 · Cited by 43
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Moreira, D. A., Santos, S. D., Leiro, V., & Pêgo, A. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041054 · Cited by 42 · cited 1×
“These in vitro models and assays are critical for determining whether nanocarriers can successfully deliver anti-in fl ammatory drugs, such as corticosteroids, NSAIDs, or more novel compounds targeting speci fi c in fl ammatory pathways, to the affected regions of the brain (Moreira et al., 2023).”
Nucleic acids presenting polymer nanomaterials as vaccine adjuvants
Comberlato, A., Paloja, K., & Bastings, M. M. C. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01222b · Cited by 41
Biomaterials for Drugs Nose–Brain Transport: A New Therapeutic Approach for Neurological Diseases
Cassano, R., Servidio, C., & Trombino, S. (2021) · Materials · doi:10.3390/ma14071802 · Cited by 40 · cited 1×
“Traditional drug delivery methods, such as oral or intravenous administration, often fail to deliver suf fi cient concentrations of drugs to the brain, limiting their therapeutic potential (Cassano et al., 2021).”
Solid Lipid Nanoparticles for Targeted Brain Drug Delivery
Patel, S. G., Patel, M. D., Patel, A. J., Chougule, M. B., & Choudhury, H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812218-1.00008-7 · Cited by 40
Toxicity and Surface Modification of Dendrimers: A Critical Review
Kharwade, R., Badole, P., Mahajan, N. M., & More, S. M. (2021) · Current Drug Delivery · doi:10.2174/1567201818666211021160441 · Cited by 39
Nong, J., Glassman, P. M., Myerson, J. W., Zuluaga‐Ramirez, V., Rodríguez-García, A., Mukalel, A. J., Omo‐Lamai, S., Walsh, L. R., Zamora, M. E., Gong, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c08275 · Cited by 37
The SH-SY5Y cell line: a valuable tool for Parkinson’s disease drug discovery
Pandey, M., Karmakar, V., Majie, A., Dwivedi, M., Md, S., & Gorain, B. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2293158 · Cited by 37
Krishna, K. V., Saha, R. N., & Dubey, S. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00430 · Cited by 36
Pourmadadi, M., Aslani, A., & Abdouss, M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125168 · Cited by 36
Gadhave, D. G., Sugandhi, V. V., & Kokare, C. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148674 · Cited by 35
Companys‐Alemany, J., Turcu, A. L., Vázquez, S., Pallàs, M., & Griñán‐Ferré, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-22963-x · Cited by 34
Nanocarriers for Delivery of Oligonucleotides to the CNS
Male, D. K., & Gromnicova, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020760 · Cited by 33
Israel, L. L., Sun, T., Braubach, O., Cox, A., Shatalova, E. S., Rashid, H.-M., Galstyan, A., Grodzinski, Z. B., Song, X. Y., Chepurna, O. M., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.001 · Cited by 33
Vargas, R., Lizano-Barrantes, C., Romero-Obón, M., València-Clua, K., Narváez-Narváez, D. A., Suñé-Negre, J. M., Pérez‐Lozano, P., García‐Montoya, E., Martínez-Martínez, N., Hernández-Munaín, C., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124686 · Cited by 32
Machine Learning for Pharmacokinetic/Pharmacodynamic Modeling
Tang, A. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.01.010 · Cited by 30 · cited 1×
“Additionally, integrating molecular dynamics simulations with AI can predict how nanocarriers will interact with cellular membranes, ensuring more accurate and safer drug delivery systems (Tang, 2023).”
PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier
Szecskó, A., Mészáros, M., Simões, B. T., Cavaco, M. C., Chaparro, C. I. P., Porkoláb, G., Castanho, M. A. R. B., Deli, M. A., Neves, V., & Veszelka, S. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00641-0 · Cited by 30
Extracellular Acidification Augments NLRP3-Mediated Inflammasome Signaling in Macrophages
Chae, B. J., Lee, K.-S., Hwang, I., & Yu, J. (2023) · Immune Network · doi:10.4110/in.2023.23.e23 · Cited by 28
Barnett, D., Bohmbach, K., Grelot, V., Charlet, A., Dallérac, G. M., Ju, Y. H., Nagai, J., & Orr, A. G. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1376-23.2023 · Cited by 28
Sun, Y., Zhang, H., Liu, R., Wang, Y., Zhang, X., Huang, R., Zhu, B., & Wu, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155802 · Cited by 28
Ding, J., Sun, Y., Li, J., Wang, H., & Mao, S. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1289541 · Cited by 27
Self-citationChoi, M., Ryu, J., Vu, H. D., Kim, D., Youn, Y.-J., Park, M. H., Huynh, P. T., Hwang, G.-B., Youn, S. W., & Jeong, Y. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914954 · Cited by 27
Traceable Self‐Assembly of Laser‐Triggered Cyanine‐Based Micelle for Synergistic Therapeutic Effect
Chen, Y., Peng, C., Lee, P., Tsai, M., Lin, C., Shih, Y., Wei, M., Luo, T., & Shieh, M. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400729 · Cited by 26 · cited 1×
“This enables the evaluation of pharmacokinetic parameters, such as the half-life of the nanocarriers in the bloodstream and their clearance rates, which are critical for assessing both the therapeutic window and safety pro fi le of the nanocarrier system (Chen et al., 2015).”
Dendrimers as nanocarriers for nucleoside analogues
Gorzkiewicz, M., & Klajnert‐Maculewicz, B. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.12.030 · Cited by 26
Cepparulo, P., Cuomo, O., Campani, V., Vinciguerra, A., Sisalli, M. J., Nele, V., Anzilotti, S., Valsecchi, V., Casamassa, A., Brancaccio, P., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102131 · Cited by 25
Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment.
Lim, A. W. Y., Schneider, L., & Loy, C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub4 · Cited by 24
Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 23 · cited 1×
“To overcome these challenges, LNPs have been developed as promising carriers for siRNA delivery (Ahmed, 2024).”
Vimal, S. K., Zuo, H., Wang, Z., Wang, H., Long, Z., & Bhattacharyya, S. (2020) · Small · doi:10.1002/smll.201906861 · Cited by 22
Self-citationBrain safety concerns of nanomedicines: The need for a specific regulatory framework
Szabat-Iriaka, B., & Borgne, M. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.011 · Cited by 22
Çınar, E., Mutluay, S. U., Baysal, İ., Gültekinoğlu, M., Ulubayram, K., Ciftci, S. Y., Tel, B. C., & Uçar, G. (2022) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.28275 · Cited by 20
Ferumoxytol Is Not Retained in Kidney Allografts in Patients Undergoing Acute Rejection
Aghighi, M., Pisani, L. J., Theruvath, A. J., Muehe, A. M., Donig, J., Khan, R., Holdsworth, S. J., Kambham, N., Concepcion, W., Grimm, P. C., et al. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1084-8 · Cited by 19
Lü, J., Lou, Y., Zhang, Y., Zhong, R., Zhang, W., Zhang, X., Wang, H., Chu, T., Han, B., & Zhong, H. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s372961 · Cited by 16
Self-citationAge-related deficits in working memory in 5xFAD mice in the Hebb-Williams maze
Fertan, E., & Brown, R. E. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113806 · Cited by 15
Shahbaz, S. K., Koushki, K., Hedayati, S. K., McCloskey, A. P., Kesharwani, P., Naderi, Y., & Sahebkar, A. (2024) · Medicinal Research Reviews · doi:10.1002/med.22064 · Cited by 15
Protein nanoparticles in molecular, cellular, and tissue imaging
Kaku, T. S., & Lim, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1714 · Cited by 14
Shen, Z., Yang, X., Lan, Y., & Chen, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231159 · Cited by 14
Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review
Mahdiabadi, S., Momtazmanesh, S., Perry, G. L., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0092 · Cited by 13
Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20106 · Cited by 13
Porret, E., Hoang, S., Denis, C., Doris, E., Hrubý, M., Novell, A., Gravel, E., & Truillet, C. (2023) · Nanoscale · doi:10.1039/d3nr01539d · Cited by 13
Kushawaha, S. K., Ashawat, M. S., & Baldi, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03253-x · Cited by 13
Li, H., Gan, R., Liu, J., Xu, D., Zhang, Q., Tian, H., Guo, H., Wang, H., Wang, Z., & Zeng, X. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101455 · Cited by 13
Self-citationGarrigós, M. M., Oliveira, F. A., Costa, C. J. S., Rodrigues, L. R., Nucci, M. P., Alves, A. H., Mamani, J. B., Rego, G. N. A., Munoz, J. M., & Gamarra, L. F. (2024) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2024ao0764 · Cited by 12
Mannucci, S., Calderan, L., Quaranta, P., Antonini, S., Mosca, F., Longoni, B., Marzola, P., & Boschi, F. (2016) · Journal of Anatomy · doi:10.1111/joa.12563 · Cited by 10
Lambidis, E., Chen, C., Baikoghli, M., Imlimthan, S., Khng, Y. C., Sarparanta, M. P., Cheng, R. H., & Airaksinen, A. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00359 · Cited by 7
Joshi, A., Agrawal, A., & Bhattacharya, S. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0096 · Cited by 6 · cited 1×
“Nanocarriers can be engineered to deliver CRISPR components (such as Cas9 and guide RNA) directly to neurons, facilitating the correction of genetic mutations that drive AD pathology (Joshi et al., 2022).”
Impact of administration route on nanocarrier biodistribution in a murine colitis model
Applegate, C. C., Deng, H., Kleszynski, B. L., Cross, T.-W., Konopka, C. J., Dobrucki, L. W., Nelson, E. R., Wallig, M. A., Smith, A. M., & Swanson, K. S. (2022) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2022.2134563 · Cited by 4
Vera, R., Hong, N., Jiang, B., Liang, G., Eckenhoff, M. F., Kincaid, H. J., Browne, V., Chellaraj, V., Gisewhite, D. R., Greenberg, M., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231337 · Cited by 4
Personalized Nanomedicine-Mediated immune regulation for Anti-Rejection in organ transplantation
Wang, H., Li, Y., Qiu, D., Pan, Q., Xu, Y., Liu, Y., & Wu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125450 · Cited by 4
Self-citationRoy, H., Maddiboyina, B., Nandi, S., Srungarapati, S., Nayak, B. S., Gade, N. J., Anjana, T. L. N. S., Vinayasri, K. M., Gummadi, A., & Haseena, S. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102810 · Cited by 2
Cited by
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Li, J., Guo, L., Cai, W., Mei, J., Liu, J., & Liu, Y. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2645830 · Cited by 21
“Consequently, regulatory agencies mandate comprehensive data beyond routine requirements, including detailed evidence on in vivo biodistribution, metabolic pathways, immunogenicity, and long-term organ-specific toxicity (Wang et al. 2025).”
Self-citationWang, M., Zhang, L., Huang, W., Huang, J., Luo, Y., & Huang, N. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103222 · Cited by 10
Microglia Mitochondrial Metabolism in Neurological Diseases
Wang, J., Gao, Y., Chen, Q., Xiong, X., Miao, S., Chen, X., Tang, Y., & Gu, L. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05640-8 · Cited by 13
“Gene therapy approaches using adeno-associated viruses (AAVs) with microglial-specific promoters could enable long-term enhancement of beneficial pathways like mitophagy or delivery of a therapeutic genes like PINK1 in Parkinson’s disease [206].”
Metadata
- Authors
- Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J.
- Affiliations
- Southwest Medical University (CN)
- Sheng Jing Hospital (CN)
- First Hospital of China Medical University (CN)
- China Academy of Chinese Medical Sciences (CN)
- Corresponding author
- He, Jiale
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2025-05-14
- Volume
- 16
- Pages
- 1591438-1591438
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC12116324
- OpenAlex
- W4410380802
- Cited by
- 27
- References
- 182
- Citations by year
- 2026: 23 · 2025: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- Alzheimer's disease, nanocarriers, targeted drug delivery, neuroinflammation, blood-brain barrier, amyloid-beta, tau pathology, blood-brain barrier penetration, inflammatory signaling, clinical translation, nanocarrier safety, regulatory challenges, precision medicine, gene therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.